Abraxane: Clinical Trials

148 trials of Abraxane, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

80 completed, 29 terminated, 13 recruiting, 10 unknown. 148 Phase 1, 65 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1148Completed 80, Terminated 29, Recruiting 13, Unknown 10, Active not recruiting 9, Withdrawn 5, Suspended 2
Phase 265Completed 32, Terminated 15, Recruiting 7, Unknown 4, Withdrawn 4, Active not recruiting 3

Follow Abraxane: new trials by email Literature Review of Abraxane trials Research Report on Abraxane

Trials (filtered) newest first · largest first

All 148 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma
Phase 1 / Phase 2WithdrawnLisata Therapeutics, Inc.2030-01-012025-06-06
DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer
Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingOhio State University Comprehensive Cancer Center502026-10-012026-10-05
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
ONT01, Gemcitabine, Nab paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingWashington University School of Medicine612026-03-252026-05-19
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
Biopsy, Biospecimen Collection, Computed Tomography - Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma
Phase 1RecruitingCity of Hope Medical Center302025-10-292026-11-10
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
ERAS-0015, ERAS-0015 in combination - Metastatic Solid Tumors
Phase 1RecruitingErasca, Inc.6002025-06-052026-11-16
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Phase 1 / Phase 2RecruitingUNC Lineberger Comprehensive Cancer Center1042025-02-062026-04-23
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
Phase 1TerminatedPfizer302024-12-102026-05-22
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
PF-07934040, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
Phase 1Active not recruitingPfizer642024-06-272026-10-13
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
Durvalumab, Carboplatin, Abequolixron - Non-Small Cell Lung Cancer
Phase 1TerminatedUNC Lineberger Comprehensive Cancer Center12024-04-012025-03-21
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
Gemcitabine, Nab-paclitaxel, YL-13027 - Metastatic Pancreatic Cancer
Phase 1TerminatedM.D. Anderson Cancer Center42024-01-222025-12-08
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
surufatinib, KN046, gemcitabine - Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Phase 1 / Phase 2UnknownShanghai Zhongshan Hospital412023-11-012024-06-14
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide - Solid Tumor, Adult, Lymphoma
Phase 1RecruitingChinese PLA General Hospital102023-07-042023-08-28
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Phase 1SuspendedNational Cancer Institute (NCI)432023-06-122026-11-03
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1RecruitingNational Cancer Institute (NCI)572023-05-182026-11-12
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Biospecimen Collection, Carboplatin, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 1 / Phase 2RecruitingVanderbilt-Ingram Cancer Center252023-05-092024-10-17
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide - Solid Tumor, Adult, EphA2 Overexpression
Phase 1Active not recruitingChinese PLA General Hospital92023-04-032025-11-24
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel - KRAS Activating Mutation, Metastatic Cancer
Phase 1 / Phase 2Active not recruitingVerastem, Inc.402023-03-222025-09-02
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Spevatamig (PT886), Paclitaxel, Gemcitabine - Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingPhanes Therapeutics3502023-03-152026-09-28
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
MSC-IFNα, Nab paclitaxel, Cyclophosphamide - Locally Advanced or Metastatic Solid Tumors
Phase 1 / Phase 2RecruitingChinese PLA General Hospital402023-02-232023-04-28
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
IOA-289 - Metastatic Pancreatic Cancer
Phase 1 / Phase 2CompletediOnctura162022-10-102026-03-30

Showing 20 of 148. Sign in to see all of them.

Conditions studied

Pancreatic Neoplasms (57)  ·  Breast Neoplasms (19)  ·  Neoplasms (19)  ·  Neoplasm Metastasis (17)  ·  Carcinoma, Non-Small-Cell Lung (16)  ·  Lung Neoplasms (9)  ·  Adenocarcinoma (8)  ·  Ovarian Neoplasms (6)  ·  Recurrence (6)  ·  Melanoma (5)  ·  Sarcoma (5)  ·  Triple Negative Breast Neoplasms (5)  ·  Colorectal Neoplasms (4)  ·  Fallopian Tube Neoplasms (4)  ·  Squamous Cell Carcinoma of Head and Neck (4)

Sponsors

M.D. Anderson Cancer Center (7)  ·  Washington University School of Medicine (6)  ·  Celgene (4)  ·  City of Hope Medical Center (4)  ·  UNC Lineberger Comprehensive Cancer Center (4)  ·  Abramson Cancer Center at Penn Medicine (3)  ·  Chinese PLA General Hospital (3)  ·  Dana-Farber Cancer Institute (3)  ·  National Cancer Institute (NCI) (3)  ·  Pfizer (3)  ·  University of California, San Francisco (3)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2)  ·  Benaroya Research Institute (2)  ·  Columbia University (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)

Countries

United States (116)  ·  Canada (7)  ·  Australia (6)  ·  China (6)  ·  Spain (6)  ·  United Kingdom (5)  ·  France (4)  ·  Germany (4)  ·  Italy (4)  ·  Netherlands (3)  ·  South Korea (3)  ·  Switzerland (3)  ·  Taiwan (3)  ·  Japan (2)  ·  Puerto Rico (2)

Top investigators

Kian-Huat Lim, M.D., Ph.D. (2)  ·  Kimberly Perez, MD (2)  ·  Peter O'Dwyer, MD (2)  ·  Thomas E. Stinchcombe, MD (2)  ·  Vincent J Picozzi, MD (2)  ·  Yang Xu, Ph.D (2)  ·  Adrienne Gropper Waks, MD (1)  ·  Amitabha Mazumder, MD (1)  ·  Amy J Chien, MD (1)  ·  Ana C Garrido-Castro (1)  ·  Ana De Jesus-Acosta, MD (1)  ·  Andrea Wang-Gillam, M.D., Ph.D. (1)

Results publications

PMID 19706807, PMID 24013936, PMID 24953566, PMID 25845992, PMID 26698868, PMID 27404453, PMID 28939558, PMID 29119276, PMID 29695765, PMID 30149366, PMID 30220407, PMID 30717707, PMID 31120501, PMID 31242873, PMID 31347292, PMID 31401903, PMID 31580386, PMID 31831564, PMID 31850192, PMID 32554315, PMID 32939319, PMID 32973176, PMID 33387490, PMID 33602685, PMID 34256279, PMID 34330715, PMID 35058882, PMID 35662283, PMID 35719960, PMID 35803294, PMID 35863672, PMID 36208017, PMID 36427020, PMID 36585452, PMID 36602796, PMID 36882775, PMID 36970055, PMID 37278638, PMID 37385724, PMID 37534996, PMID 38547893, PMID 38902994, PMID 39263892, PMID 39418340, PMID 39863139, PMID 41133726, PMID 41197185, PMID 41271741, PMID 41297162, PMID 41315271

NIH funding

2015 (3), P30CA033572 (2), P30CA068485 (2), P50CA196510 (2), 2016 (1), 2019 (1), P30CA014089 (1), P30CA014599 (1), P30CA022453 (1), P30CA072720 (1), P50CA272213 (1), R01CA199646 (1), R01CA290435 (1), U01CA168426 (1), U19CA021239 (1)